Insider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells 11,442 Shares of Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Camille L. Bedrosian sold 11,442 shares of the firm’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $3.20, for a total value of $36,614.40. Following the completion of the sale, the insider now owns 143,801 shares of the company’s stock, valued at $460,163.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Amylyx Pharmaceuticals Stock Down 1.0 %

AMLX stock traded down $0.03 during mid-day trading on Wednesday, reaching $3.03. 738,408 shares of the company traded hands, compared to its average volume of 2,086,326. The firm’s 50 day moving average price is $2.37 and its 200 day moving average price is $2.15. The stock has a market cap of $206.06 million, a price-to-earnings ratio of -2.83 and a beta of -0.62. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $1.58 and a fifty-two week high of $19.95.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. The company had revenue of ($1.02) million for the quarter, compared to analysts’ expectations of $18.83 million. During the same period in the previous year, the firm earned $0.31 EPS. On average, analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of hedge funds have recently bought and sold shares of AMLX. AQR Capital Management LLC raised its holdings in shares of Amylyx Pharmaceuticals by 2,768.0% in the second quarter. AQR Capital Management LLC now owns 3,340,943 shares of the company’s stock valued at $6,348,000 after purchasing an additional 3,224,454 shares during the last quarter. Almitas Capital LLC bought a new stake in Amylyx Pharmaceuticals in the 2nd quarter worth about $3,617,000. Acadian Asset Management LLC purchased a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at about $2,300,000. Farallon Capital Management LLC bought a new position in shares of Amylyx Pharmaceuticals during the 1st quarter worth approximately $3,267,000. Finally, XTX Topco Ltd bought a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter worth approximately $400,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Amylyx Pharmaceuticals in a report on Wednesday, July 10th. The Goldman Sachs Group upped their target price on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a “neutral” rating in a research report on Friday, July 12th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Amylyx Pharmaceuticals has an average rating of “Hold” and an average price target of $17.60.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.